Impact of Corticosteroids in Coronavirus Disease 2019 Outcomes

[1]  G. Raghu,et al.  Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020) , 2020, European Respiratory Review.

[2]  Xixin Yan,et al.  Clinical characteristics and treatment of critically ill patients with COVID-19 in Hebei. , 2020, Annals of palliative medicine.

[3]  F. Zheng,et al.  Clinical characteristics of coronavirus disease 2019 in patients aged 80 years and older , 2020, Journal of Integrative Medicine.

[4]  Z. Duan,et al.  Duration of SARS‐CoV‐2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID‐19 , 2020, Journal of medical virology.

[5]  Zhihang Peng,et al.  Clinical Use of Short-Course and Low-Dose Corticosteroids in Patients With Non-severe COVID-19 During Pneumonia Progression , 2020, Frontiers in Public Health.

[6]  Lanjuan Li,et al.  Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study , 2020, The Journal of infectious diseases.

[7]  S. Al-Youha,et al.  Characteristics, risk factors and outcomes among the first consecutive 1096 patients diagnosed with COVID-19 in Kuwait , 2020, EClinicalMedicine.

[8]  J. Chan,et al.  Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19 , 2020, International Journal of Infectious Diseases.

[9]  Xinyu Song,et al.  High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  Yushu Wang,et al.  The influence of corticosteroid on patients with COVID-19 infection: A meta-analysis , 2020, The American Journal of Emergency Medicine.

[11]  E. Múñez-Rubio,et al.  A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality , 2020, Antimicrobial Agents and Chemotherapy.

[12]  Jennifer L. Bell,et al.  Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report , 2020, medRxiv.

[13]  E. Múñez-Rubio,et al.  A Retrospective Controlled Cohort Study of the Impact of Glucocorticoid Treatment in SARS-CoV-2 Infection Mortality , 2020, Antimicrobial Agents and Chemotherapy.

[14]  M. Salesi,et al.  The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study , 2020, DARU Journal of Pharmaceutical Sciences.

[15]  Chunlin Cai,et al.  Treatment strategies of hospitalized patients with coronavirus disease-19 , 2020, Aging.

[16]  D. Leduc,et al.  Corticosteroids in Patients With COVID-19: What About the Control Group? , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  P. Pelosi,et al.  Bloodstream infections in critically ill patients with COVID‐19 , 2020, European journal of clinical investigation.

[18]  G. Zhen,et al.  Predictors of fatality including radiographic findings in adults with COVID-19 , 2020, Respiratory Research.

[19]  I. Al-Zakwani,et al.  Clinical characteristics and outcomes of the first 63 adult patients hospitalized with COVID-19: An experience from Oman , 2020, Journal of Infection and Public Health.

[20]  Tingmei Wang,et al.  Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests , 2020, Travel Medicine and Infectious Disease.

[21]  T. Qu,et al.  Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series , 2020, Critical Care.

[22]  Qijun Wu,et al.  A Retrospective Analysis of the Clinical and Epidemiological Characteristics of COVID-19 Patients in Henan Provincial People's Hospital, Zhengzhou, China , 2020, Frontiers in Medicine.

[23]  Y. Hu,et al.  Effects of Corticosteroid Treatment for Non-Severe COVID-19 Pneumonia: A Propensity Score-Based Analysis. , 2020, Shock.

[24]  R. Jin,et al.  Clinical characteristics of Coronavirus Disease 2019 patients in Beijing, China , 2020, PloS one.

[25]  Q. Lv,et al.  Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study , 2020, BMJ open diabetes research & care.

[26]  H. Shan,et al.  Successful use of methylprednisolone for treating severe COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[27]  S. Ayis,et al.  The association between treatment with heparin and survival in patients with Covid-19 , 2020, Journal of Thrombosis and Thrombolysis.

[28]  N. Ortego Centeno,et al.  Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection. , 2020, Medicina clinica.

[29]  Luhuan Yang,et al.  Epidemiological and clinical features of 200 hospitalized patients with corona virus disease 2019 outside Wuhan, China: A descriptive study , 2020, Journal of Clinical Virology.

[30]  Huajun Wu,et al.  Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019 , 2020, Journal of clinical pharmacy and therapeutics.

[31]  Jianguo Wu,et al.  Epidemiological and Clinical Characteristics of Patients With Coronavirus Disease-2019 in Shiyan City, China , 2020, Frontiers in Cellular and Infection Microbiology.

[32]  Zhu Jin,et al.  Effects of methylprednisolone use on viral genomic nucleic acid negative conversion and CT imaging lesion absorption in COVID‐19 patients under 50 years old , 2020, Journal of medical virology.

[33]  N. Dangayach,et al.  Coronavirus disease 19 in minority populations of Newark, New Jersey , 2020, International Journal for Equity in Health.

[34]  J. Montastruc,et al.  Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France , 2020, Therapies.

[35]  G. Guyatt,et al.  Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis , 2020, Canadian Medical Association Journal.

[36]  I. Takeuchi,et al.  Clinical course of 2019 novel coronavirus disease (COVID-19) in individuals present during the outbreak on the Diamond Princess cruise ship , 2020, Journal of Infection and Chemotherapy.

[37]  Cezmi A Akdis,et al.  Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19 , 2020, Allergy.

[38]  Junfen Fan,et al.  Clinical features of patients with coronavirus disease 2019 from a designated hospital in Beijing, China , 2020, Journal of medical virology.

[39]  Rachel M. Kenney,et al.  Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19 , 2020, medRxiv.

[40]  R. Gale,et al.  Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis , 2020, Leukemia.

[41]  H. Cai,et al.  Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China , 2020, Journal of Zhejiang University-SCIENCE B.

[42]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[43]  Jun Zhang,et al.  Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China , 2020, Journal of Clinical Virology.

[44]  Baoju Wang,et al.  A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia , 2020, Signal Transduction and Targeted Therapy.

[45]  Reem A Mustafa,et al.  Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[46]  Kyung Soo Hong,et al.  Clinical Features and Outcomes of 98 Patients Hospitalized with SARS-CoV-2 Infection in Daegu, South Korea: A Brief Descriptive Study , 2020, Yonsei medical journal.

[47]  Soumitra Sengupta,et al.  Characterization and clinical course of 1000 patients with COVID-19 in New York: retrospective case series , 2020, medRxiv.

[48]  M. Moghadami,et al.  Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the South of Iran , 2020, BMC Infectious Diseases.

[49]  Hong Zhang,et al.  The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single‐centre, retrospective, observational study in Wuhan , 2020, Diabetes, obesity & metabolism.

[50]  A. Sestokas,et al.  Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients , 2020, ASAIO journal.

[51]  C. Scavone,et al.  SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment , 2020, International Immunopharmacology.

[52]  Felipe García,et al.  COVID-19 in patients with HIV: clinical case series , 2020, The Lancet HIV.

[53]  Yimin Li,et al.  SARS-CoV-2 Viral Load in Clinical Samples from Critically Ill Patients , 2020, American journal of respiratory and critical care medicine.

[54]  Haibo Xu,et al.  Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China , 2020, Critical Care.

[55]  Jing Shi,et al.  Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan , 2020, Journal of Allergy and Clinical Immunology.

[56]  Yongsheng Li,et al.  Adjuvant corticosteroid therapy for critically ill patients with COVID-19 , 2020, Critical Care.

[57]  Ke Liang,et al.  Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study , 2020, The journals of gerontology. Series A, Biological sciences and medical sciences.

[58]  Xin Li,et al.  COVID-19 with Different Severities: A Multicenter Study of Clinical Features , 2020, American journal of respiratory and critical care medicine.

[59]  A. Pan,et al.  Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19 , 2020, Journal of Infection.

[60]  Chang Hu,et al.  Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.

[61]  Jun Liu,et al.  Factors associated with prolonged viral RNA shedding in patients with COVID-19 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  Shirong Li,et al.  Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19) , 2020, The Medical journal of Australia.

[63]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[64]  Sheng Zhang,et al.  Clinical characteristics of 60 discharged cases of 2019 novel coronavirus-infected pneumonia in Taizhou, China , 2020, Annals of translational medicine.

[65]  Huihui Ren,et al.  Clinical characteristics and outcomes of patients with severe covid-19 with diabetes , 2020, BMJ Open Diabetes Research & Care.

[66]  Zhenwei Yang,et al.  The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis , 2020, Journal of Infection.

[67]  M. Cherkaoui,et al.  Asymptomatic COVID-19 Infection Management: The Key to Stop COVID-19 , 2020, Journal of Clinical and Experimental Investigations.

[68]  G. Ippolito,et al.  COVID-19, SARS and MERS: are they closely related? , 2020, Clinical Microbiology and Infection.

[69]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[70]  Hui Guo,et al.  Risk-adapted Treatment Strategy For COVID-19 Patients , 2020, International Journal of Infectious Diseases.

[71]  Y. Xiong,et al.  Clinical features and treatment of COVID‐19 patients in northeast Chongqing , 2020, Journal of medical virology.

[72]  Wei Liu,et al.  Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study , 2020, Chinese medical journal.

[73]  Q. Ding,et al.  The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China , 2020, Journal of medical virology.

[74]  W. Tu,et al.  Clinical Features and Short-term Outcomes of 102 Patients with Corona Virus Disease 2019 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[76]  Guihua Zhang,et al.  A report of clinical diagnosis and treatment of nine cases of coronavirus disease 2019 , 2020, Journal of medical virology.

[77]  Jun Zhang,et al.  Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression , 2020, International Journal of Infectious Diseases.

[78]  Baoping Yu,et al.  Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study , 2020, BMC Infectious Diseases.

[79]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[80]  Yixiao Lin,et al.  Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients , 2020, Chinese medical journal.

[81]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[82]  王华英,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[83]  Ting Yu,et al.  Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study , 2020, The Lancet Respiratory Medicine.

[84]  S. Zhang,et al.  Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series , 2020, BMJ.

[85]  Lijuan Xiong,et al.  Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.

[86]  J. González-Martín,et al.  Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. , 2020, The Lancet. Respiratory medicine.

[87]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[88]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[89]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[90]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[91]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[92]  F. Shan,et al.  Epidemiology and clinical course of COVID-19 in Shanghai, China , 2020, Emerging microbes & infections.

[93]  Kaijin Xu,et al.  Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19) , 2020 .

[94]  SEPSIS BULLETIN,et al.  Surviving Sepsis Campaign : Guidelines on the Management of Critically Ill Adults with Coronavirus Disease , 2020 .

[95]  D. Annane,et al.  Corticosteroids for treating sepsis in children and adults. , 2019, The Cochrane database of systematic reviews.

[96]  Natalie S Blencowe,et al.  RoB 2: a revised tool for assessing risk of bias in randomised trials , 2019, BMJ.

[97]  Gavin D Perkins,et al.  Guidelines on the management of acute respiratory distress syndrome , 2019, BMJ Open Respiratory Research.

[98]  R. Siemieniuk,et al.  Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS , 2018, Journal of Intensive Care.

[99]  M. Egi,et al.  The clinical practice guideline for the management of ARDS in Japan , 2017, Journal of Intensive Care.

[100]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[101]  G. Van den Berghe,et al.  Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. , 2017, Critical care medicine.

[102]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[103]  Emily E. Sickbert-Bennett,et al.  Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza viruses, A(H5N1) and A(H7N9) , 2016, American Journal of Infection Control.

[104]  Dan Jackson,et al.  Extending DerSimonian and Laird's methodology to perform multivariate random effects meta‐analyses , 2009, Statistics in medicine.

[105]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration , 2009, BMJ : British Medical Journal.

[106]  J. Chan,et al.  Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong , 2006, Journal of Infection.

[107]  Paul Garner,et al.  SARS: Systematic Review of Treatment Effects , 2006, PLoS medicine.

[108]  V. Wong,et al.  Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.

[109]  M. Chan-yeung,et al.  High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. , 2003, American journal of respiratory and critical care medicine.

[110]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.